{"schema_version":"secwatch.filing_event.v1","accession":"0001770787-23-000051","form_type":"8-K","ticker":"TXG","cik":"0001770787","company_name":"10x Genomics, Inc.","filed_at":"2023-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.373877+00:00","generated_at":"2026-06-09T00:43:31.270044+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"10x Genomics Q3 revenue $153.6M (+17% YoY), net loss $93.0M; raises FY2023 guidance","bullets":["Q3 2023 revenue $153.6M, up 17% YoY; raised FY2023 guidance to $610-625M.","Gross margin fell to 62% from 77% YoY due to product mix from Xenium instrument placements.","Operating loss $94.8M ($40.0M prior year); includes $41.4M in-process R&D and $40.2M stock comp.","Net loss $93.0M vs $41.9M; cash & securities $356.9M as of Sep 30.","Xenium platform driving demand; launched new panel configurations and Beckman Coulter partnership."],"urls":{"canonical":"https://secwatch.observer/filing/0001770787-23-000051","json":"https://secwatch.observer/filing/0001770787-23-000051.json","markdown":"https://secwatch.observer/filing/0001770787-23-000051.md","text":"https://secwatch.observer/filing/0001770787-23-000051.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000051/0001770787-23-000051-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000051/txg-20231102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T00:43:31.270044+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7e4585982269adeef9e2bc52536e491169ad606f","claim":"10x Genomics, Inc. reported for the third quarter ended September 30, 2023 results: revenue $153.6 million, net income Net loss was $93.0 million. Guidance raised.","evidence_excerpt":"Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today reported financial results for the third quarter ended September 30, 2023. Recent Highlights • Revenue was $153.6 million for the third quarter, a 17% increase over the corresponding period of 2022, driven by Xenium momentum. • Advanced Xenium gene panel strategy, launching new targeted and custom","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1770787/000177078723000051/0001770787-23-000051-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"for the third quarter ended September 30, 2023"},{"label":"Revenue","value":"$153.6 million"},{"label":"Net income","value":"Net loss was $93.0 million"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}